Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19

Chun Fan Chen, Chian Hsu Chien, Yi Ping Yang, Shih Jie Chou, Mong Lien Wang, The Ia Huo, Chih Ching Lin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.

Original languageEnglish
Pages (from-to)710-711
Number of pages2
JournalJournal of the Chinese Medical Association
Volume83
Issue number8
DOIs
StatePublished - Aug 2020

Keywords

  • Coronavirus disease 2019
  • Dipeptidyl peptidase-4 inhibitors
  • Severe acute respiratory syndrome coronavirus 2

Fingerprint

Dive into the research topics of 'Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19'. Together they form a unique fingerprint.

Cite this